药明生物宣布投资8000万新币在新加坡新建生产基地
WuXi Biologics to Invest S$80 Million to Establish a Biologics Manufacturing Facility in Singapore
(*Please scroll down for English news.)
新加坡，上海，2018年5月22日
– 国际化战略再下一城- 首次在亚洲地区布局海外生产基地
全球领先的开放式生物技术平台公司药明生物（WuXi Biologics, 2269.HK）今日宣布，公司计划投资8,000万新币（约合3.8亿人民币）在新加坡新建现代化生物制药生产基地，并创造约150个工作岗位。
这是药明生物在全球范围布局的第十个生产基地（药明生物十厂），也是药明生物首次在中国之外的亚洲地区新建生产基地新加坡制药公司有哪些，同时也是公司继后投资建设的第二个海外生产基地。
签约仪式现场
（左起：药明生物董事长李革博士、新加坡经济发展局主席马宣仁博士、药明生物首席执行官陈智胜博士）
药明生物总部位于中国江苏无锡市，为全球生物制药公司和生物技术公司提供全方位的端到端研发服务，其使命是加快和转变生物制药发现、开发及生产，造福全球患者。
即将开建的药明生物新加坡基地将继续采用全球领先的一次性生物反应器，并率先应用“新一代生物制药生产技术”（连续生产工艺）开展商业化生产，致力于成为亚洲领先的生物制药“未来工厂”。该基地总产能将达到4,500升新加坡制药公司有哪些，包括2个2,000升流加细胞培养反应器与1个500升灌流工艺生物反应器，基地建成后将拥有生物工艺开发实验室，并同时具备临床样品生产和小规模商业化生产的能力。此项目的推进得到了新加坡经济发展局（EDB）的大力支持。
“我们很高兴药明生物选择在新加坡投资建设其亚洲地区首个海外生产基地，并引入全球领先的下一代生物工艺技术平台。药明生物的选择充分证明新加坡在生物医药领域强大的人才储备和领先的生物制药生产实力，相信药明生物能有力加强新加坡及周边地区的生物技术创新生态系统建立。”新加坡经济发展局主席马宣仁博士指出。
“新加坡是公认的亚洲最富活力的生物医药中心之一。药明生物新加坡基地在公司国际化战略中至关重要，有助于确保公司生产的最高质量标准生物药能通过强大的供应链网络，造福全球患者。非常感谢新加坡各界人士对我们的大力支持。在各方强有力的支持下，我们相信这个令人兴奋的项目将实现快速推进。”药明生物董事长李革博士表示。
药明生物首席执行官陈智胜博士表示：“新基地将在不久的将来满足药明生物日益增长的生物制药开发及生产需求。我们非常高兴于新加坡投建公司在亚洲的第一个海外生产基地，从而更好地赋能当地及亚洲地区合作伙伴加速生物药开发进程。我们致力于将药明生物打造成为全球生物制药领域更宽、更广、更深的生物制药能力和技术平台，赋能当地及全球合作伙伴。”
关于药明生物
药明生物作为一家香港上市公司，是全球领先的开放式、一体化生物制药能力和技术赋能平台。公司为全球生物制药公司和生物技术公司提供全方位的端到端研发服务，帮助任何人、任何公司发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。如需更多信息，请访问：。
WuXi Biologics to Invest S$80 Million to Establish a Biologics Manufacturing Facility in Singapore
SINGAPORE and SHANGHAI,May 22, 2018
– WuXi Biologics’ first overseas site in Asia
WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it is to invest S$80 million(equivalent to approximately USD$60 million) and hire approximately 150 employees to establish a state-of-the-art biologicsmanufacturing facility in Singapore. It will be the 10th global drug substance manufacturing facility of WuXi Biologics (MFG10).
Headquartered in Wuxi city, Jiangsu province, China, WuXi Biologics is a leading global platform company providing end-to-end solutions for biologics with a mission to accelerate and transform biologics discovery, development and manufacturing to benefit patients around the world.
This state-of-the-art “facility of the future” will be built upon the novel approach WuXi Biologics has pioneered deploying single-use bioreactors. It is also designed to be able to run continuous bioprocessing, a next generation manufacturing technology to be first implemented in Asia outside of China. A total of approximately 4,500 L bioreactor capacity will be installed with two 2,000 L traditional fed-batch and one 500 L perfusion based continuous processing. This facility will be able to handle both clinical and small volume commercial production. An early-stage bioprocess development lab will also be included.
The new manufacturing facility, supported by the Singapore Economic Development Board, is the Company’s first overseas site in Asia and second site outside of China.
“We are delighted that WuXi Biologics has chosen Singapore as its first overseas manufacturing site in Asia. This will introduce the company’s next-generation bioprocessing technology platform to this region. WuXi Biologics’ decision is a testament to Singapore’s strong talent pool for the biomedical sciences sector and our capabilities in advanced manufacturing. Its presence here will also strengthen our ecosystem for supporting biotech companies from Singapore and beyond,” saidDr. Beh Swan Gin, Chairman of EDB.
“Singapore is acknowledged as a leader in the biopharmaceutical industry. The new site plays a key role in WuXi Biologics’ global biomanufacturing network to ensure that biologics are manufactured at the highest quality and with a robust supply chain to benefit patients worldwide. We are grateful for all the support local agencies and the talented people here have provided for us. With the strong support, we believe we can quickly push forward this exciting project,” said Dr. Ge Li, Chairman of WuXi Biologics.
Dr. Chris Chen, CEO of WuXi Biologics, added, “The new site will undoubtedly meet WuXi Biologics’ growing need for biologics development and manufacturing in the near future. We are all very excited to initiate our first overseas Asian site in Singapore to enable local companies and expedite biologics development in Asia. We are committed to becoming the most comprehensive capability and technology platform in the global biologics industry to enable both local and global partners.”
About WuXi Biologics
WuXi Biologics, a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. For more information on WuXi Biologics, please visit
注：本信息不构成药明生物的信息披露或投资建议
发布者：sgadmin，本文为作者独立观点，不代表本站立场。转载请注明出处：https://www.sgstarting.com/archives/5790
